Exome Asset Management LLC Makes New $3.40 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC)

Exome Asset Management LLC bought a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 36,700 shares of the biotechnology company’s stock, valued at approximately $3,395,000. Blueprint Medicines accounts for approximately 2.3% of Exome Asset Management LLC’s portfolio, making the stock its 15th biggest holding. Exome Asset Management LLC owned approximately 0.06% of Blueprint Medicines at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Triad Wealth Partners LLC bought a new stake in shares of Blueprint Medicines in the 2nd quarter valued at about $27,000. Quarry LP purchased a new stake in shares of Blueprint Medicines during the third quarter valued at about $32,000. Covestor Ltd boosted its holdings in shares of Blueprint Medicines by 206.7% in the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 403 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Blueprint Medicines in the 3rd quarter worth approximately $108,000. Finally, CWM LLC raised its stake in shares of Blueprint Medicines by 114.6% during the 2nd quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 590 shares in the last quarter.

Insiders Place Their Bets

In other news, insider Fouad Namouni sold 3,633 shares of the firm’s stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the sale, the insider now owns 69,070 shares in the company, valued at $6,169,332.40. This trade represents a 5.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kate Haviland sold 2,353 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $96.60, for a total value of $227,299.80. Following the completion of the transaction, the chief executive officer now owns 150,824 shares of the company’s stock, valued at $14,569,598.40. The trade was a 1.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,260 shares of company stock valued at $768,057 in the last three months. 4.21% of the stock is currently owned by insiders.

Blueprint Medicines Price Performance

Shares of NASDAQ BPMC opened at $93.19 on Friday. The firm has a 50-day simple moving average of $92.03 and a 200-day simple moving average of $97.52. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $5.92 billion, a price-to-earnings ratio of -44.17 and a beta of 0.59. Blueprint Medicines Co. has a 52 week low of $72.24 and a 52 week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The company had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. During the same quarter in the prior year, the firm earned ($2.20) EPS. Blueprint Medicines’s quarterly revenue was up 126.5% on a year-over-year basis. On average, equities analysts predict that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Guggenheim reaffirmed a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday. UBS Group assumed coverage on Blueprint Medicines in a report on Thursday, October 24th. They issued a “neutral” rating and a $88.00 price target for the company. JMP Securities restated a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a report on Monday, December 9th. HC Wainwright reiterated a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, November 15th. Finally, StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $122.11.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.